Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Pharming N.V.(US:PHAR) Globenewswire·2025-11-06 06:00Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS wi ...